PEC, O., Petr BOB, J. SIMEK and J. RABOCH. Dissociative states in borderline personality disorder and their relationships to psychotropic medication. Neuropsychiatric Disease and Treatment. Auckland: Dove Medical Press Ltd., 2018, vol. 14, No 2018, p. 3253-3257. ISSN 1178-2021. Available from: https://dx.doi.org/10.2147/NDT.S179091.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Dissociative states in borderline personality disorder and their relationships to psychotropic medication
Authors PEC, O. (203 Czech Republic), Petr BOB (203 Czech Republic, guarantor, belonging to the institution), J. SIMEK (203 Czech Republic) and J. RABOCH (203 Czech Republic).
Edition Neuropsychiatric Disease and Treatment, Auckland, Dove Medical Press Ltd. 2018, 1178-2021.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30103 Neurosciences
Country of publisher New Zealand
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.228
RIV identification code RIV/00216224:14740/18:00106588
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.2147/NDT.S179091
UT WoS 000451245400002
Keywords in English dissociation; stress; antipsychotics; antidepressants
Tags rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 13/3/2019 11:06.
Abstract
Background: According to recent data, dissociation may play an important role in borderline personality disorder (BPD), nevertheless specific influences of psychotropic medication on dissociative symptoms in BPD and their therapeutic indications are largely unknown. The purpose of this study was to assess relationships of dissociative symptoms in BPD patients with levels of psychotropic medication and compare these results with a subgroup of patients with schizophrenia. Materials and methods: In this study, we investigated 52 BPD patients and compared the results with a control group of 36 schizophrenia patients. In all participants, we assessed actual day doses of antipsychotic medication in chlorpromazine equivalents and antidepressant medication in fluoxetine equivalents. Dissociative symptoms were measured by Dissociative Experiences Scale (DES), and other psychopathological symptoms were measured using Health of the Nation Outcome Scales. Results: Results indicate that dissociative symptoms measured by DES were significantly correlated with antipsychotic medication (Spearman R=0.45, P<0.01) in chlorpromazine equivalents and antidepressant medication in fluoxetine equivalents (0.36, P<0.01). These relationships between medication and dissociative symptoms were not found in the control group of schizophrenia patients. Conclusion: The results suggest that levels of antipsychotic medication and antidepressant medication are significantly associated with dissociative symptoms in BPD but not in schizophrenia.
PrintDisplayed: 15/7/2024 02:01